These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1429338)

  • 1. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies.
    Baldwin DR; Wise R; Andrews JM; Honeybourne D
    J Antimicrob Chemother; 1992 Jul; 30(1):67-71. PubMed ID: 1429338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil.
    Gehanno P; Andrews JM; Ichou F; Sultan E; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():47-51. PubMed ID: 2292530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil.
    Dumont R; Guetat F; Andrews JM; Sultan E; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():41-6. PubMed ID: 2292529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
    Geddes AM
    Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefpodoxime proxetil concentrations in head and neck tissues.
    Theopold HM; Matthias C; Adam D
    Infection; 1991; 19(1):41-3. PubMed ID: 2013507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil.
    Couraud L; Andrews JM; Lecoeur H; Sultan E; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():35-40. PubMed ID: 2292528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefpodoxime proxetil in upper respiratory tract infections.
    Bergogne-Berezin E
    Drugs; 1991; 42 Suppl 3():25-33. PubMed ID: 1726205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs.
    Brown SA; Boucher JF; Hubbard VL; Prough MJ; Flook TF
    J Vet Pharmacol Ther; 2007 Aug; 30(4):320-6. PubMed ID: 17610405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the pharmacokinetics of cefpodoxime proxetil.
    Borin MT
    Drugs; 1991; 42 Suppl 3():13-21. PubMed ID: 1726203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Frampton JE; Brogden RN; Langtry HD; Buckley MM
    Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid pharmacokinetics of cefpodoxime proxetil in piglets.
    Abdel-Rahman SM; Maxson S; Teo C; Hubbard AE; Kearns GL
    J Clin Pharmacol; 2000 Mar; 40(3):290-5. PubMed ID: 10709158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
    Chantot JF; Mauvais P
    Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.
    Borin MT; Hughes GS; Patel RK; Royer ME; Cathcart KS
    J Clin Pharmacol; 1991 Dec; 31(12):1137-45. PubMed ID: 1761737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.
    Saathoff N; Lode H; Neider K; Depperman KM; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1992 Apr; 36(4):796-800. PubMed ID: 1354432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.
    Tremblay D; Dupront A; Ho C; Coussediere D; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():21-8. PubMed ID: 2292526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients.
    Muller-Serieys C; Bancal C; Dombret MC; Soler P; Murciano G; Aubier M; Bergogne-Berezin E
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2099-103. PubMed ID: 1444291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.
    Höffler D; Koeppe P; Corcilius M; Przyklinik A
    Infection; 1990; 18(3):157-62. PubMed ID: 2365467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.
    Borin MT; Hughes GS; Spillers CR; Patel RK
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1094-9. PubMed ID: 2393268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.